The FDA has approved Biogen's Alzheimer's drug, aducanumab, which will be marketed as Aduhelm. Why it matters: Aduhelm is the first federally approved Alzheimer's treatment in roughly 18 years, but there is no conclusive evidence the drug slows the decline of memory and brain function.
Trending:
FDA approves Biogen's Alzheimer's drug despite lack of evidence